Prevention The most important measure taken for treatment of<unk> -phosphoglucanate dehydrogenase is prevention. Avoidance of chemical exposures to drugs and foods that have the potential to cause hemolysis. Although some foods and supplements have antioxidant properties, their use does not decrease the severity of G6PD deficiency. Diagnosis is difficult during haemolytic episodes since reticulocytes have increased levels of enzymes and may produce erroneously normal results. Testing can be useful after a steady state is reached (about six weeks after the most recent episode of haemolysis), including a G6PD assay to confirm a diagnosis and G6PD spectrophotometry to detect the level of activity. Vaccinations against some common pathogens (e.g. hepatitis A and hepatitis B) may prevent infection-induced attacks. Blood transfusion In the acute phase of hemolysis, blood transfusions might be necessary, or even dialysis in acute kidney injury. Blood transfusion is an important symptomatic measure, as the transfused red cells are generally not<unk> PGD deficient and will live a normal lifespan in the recipient's circulation.
6-phosphogluconate dehydrogenase deficiency
Glutaminase deficiency
Ribose-5-phosphate isomerase deficiency
Pyruvate kinase deficiency
Malonyl-CoA decarboxylase deficiency
Pyruvate carboxylase deficiency
3-Methylcrotonyl-CoA carboxylase deficiency
D-glycerate dehydrogenase deficiency